A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of C21 in patients with Idiopathic Pulmonary Fibrosis (IPF)
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs C-21 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Vicore Pharma
- 06 Nov 2019 Last checked against European Clinical Trials Database record.
- 02 Nov 2019 Status changed from not yet recruiting to discontinued.
- 11 Jul 2018 New trial record